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Mutations in the MEFV gene, which encodes the protein named pyrin (also called
marenostrin or TRIM20), are associated with the autoinflammatory disease familial
Mediterranean fever (FMF). Recent genetic and immunologic studies uncovered novel
functions of pyrin and raised several new questions in relation to FMF pathogenesis.
The disease is clinically heterogeneous reflecting the complexity and multiplicity of pyrin
functions. The main functions uncovered so far include its involvement in innate immune
response such as the inflammasome assemblage and, as a part of the inflammasome,
sensing intracellular danger signals, activation of mediators of inflammation, and
resolution of inflammation by the autophagy of regulators of innate immunity. Based
on these functions, the FMF-associated versions of pyrin confer a heightened sensitivity
to a variety of intracellular danger signals and postpone the resolution of innate immune
responses. It remains to be demonstrated, however, what kind of selective advantage
the heterozygous carriage conferred in the past to be positively selected and maintained
in populations from the Mediterranean basin.
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INTRODUCTION
Autoinflammatory diseases are a group of genetically determined multisystem disorders caused
primarily by the dysfunctions in innate immunity. These rare disorders are characterized
by recurrent episodes of generalized inflammation and fever in the absence of infectious or
autoimmune causes (McDermott et al., 1999; Brydges and Kastner, 2006). Familial Mediterranean
fever (FMF; MIM 294100) is one of the most common and best characterized hereditary
autoinflammatory syndromes (Ting et al., 2006; Masters et al., 2009). FMF is an ethnically restricted
disease, which predominantly affects people of Mediterranean descent, mainly Armenians, Turks,
Arabs and Jews. The carrier rate in these populations is estimated to be as high as 1:5 to 1:7
(Daniels et al., 1995; Gershoni-Baruch et al., 2001; Yilmaz et al., 2001; Sarkisian et al., 2008). Other
Mediterranean populations are less affected by the disease, although the number of cases is still
substantial (Touitou, 2001; La Regina et al., 2003).
GENETICS OF FMF
Familial Mediterranean fever has long being considered as an autosomal recessive disease caused
by mutations in the MEFV gene, which is composed of 10 exons and encodes a 781 amino
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acids protein called pyrin or marenostrin or TRIM20 (The French
FMF Consortium, 1997; The International FMF Consortium,
1997). According to the INFEVERS database, more than 60
FMF-associated mutations have been identified so far, with
the majority of them being extremely rare mutations (http:
//fmf.igh.cnrs.fr/infevers/). The FMF-associated mutations are
predominantly located within exon 10 of the gene, and they
primarily result in amino acid substitutions. The phenotypic
variability of the disease is thought to be partially associated
with particular mutations and allelic heterogeneity (Dewalle et al.,
1998; Shohat et al., 1999). The most frequent mutations causing
FMF are the five missense mutations: in exon 10 these are M694V,
M694I, V726A, and M680I and in exon 2 – E148Q (Touitou,
2001). Among these five mutations, M694V is associated with
a more severe form of the disease (Shinar et al., 2000), and
E148Q mutation – with a milder form of the disease (Touitou,
2001).
Despite being long considered as an autosomal recessive
disorder, there are some cases with the involvement of only one
MEFV heterozygous mutation and even without any apparent
MEFV mutation (Booty et al., 2009; Marek-Yagel et al., 2009; Ben-
Zvi et al., 2015). Although the genetic defect causing the disease
is well-known, a broad spectrum of MEFV-associated phenotypes
suggest additional genes or immune factors, which may modulate
the innate immune response in FMF. A growing number of
studies confirm this hypothesis. It has been suggested that major
histocompatibility complex class (HLA) I chain-related gene A
has a modifier effect on the disease phenotype (Turkcapar et al.,
2007). More recently, differential effects of HLA class I and class
II alleles on FMF such as subsets of clinical forms and response to
colchicines treatment have been demonstrated for the Japanese
population (Yasunami et al., 2015).
The high carrier frequency in affected populations suggests
the selective advantage conferred by the heterozygous state such
as protection against presumptive pathogen(s). Comparative
analyses of amino acid substitutions in the ret finger protein
(rfp) domain of pyrin among primates and diseased people have
demonstrated that some human mutations actually represent the
recapitulation to the ancestral amino acid states and these exist as
wild type in other species (Schaner et al., 2001). Inspection of the
dN/dS ratios performed by the authors revealed the signature of
episodic positive selection. Another study of population genetics
of FMF involving the sequence analysis of a larger MEFV region,
from exon 5 to the 3′-UTR, essentially supported the hypothesis
of heterozygote advantage/overdominance for MEFV mutations
(Fumagalli et al., 2009). The meta-analysis of population genetics
in FMF suggests that the mutations are not uniformly distributed
in various populations and differ in phenotypes, neutrality and
other population genetics characteristics (Papadopoulos et al.,
2008). The authors identified Jews as the candidate population
for founder effects in MEFV mutations due to genetic isolation
and genetic drift.
Positive selection to maintain the high frequency of the
heterozygotes should be sufficiently strong to overcome the
negative effects such as the increased morbidity and mortality
rates among the homozygotes and compounded heterozygotes
(Twig et al., 2014). There have been suggestions that the mutated
forms of the protein may confer an increased protection against
tuberculosis (Cattan, 2003) or brucellosis (Ross, 2007) but none
had direct evidence provided. Other potential effects of the
mutation carrier state are thought may be associated with the
protection against asthma (Brenner-Ullman et al., 1994), atopy
(Sackesen et al., 2004), or allergy (Kalyoncu et al., 2006). But it
is not clear then why this protection mechanism against allergic
diseases had not emerged worldwide but remained restricted to
the existing geographical and ethnical boundaries.
PYRIN: STRUCTURE AND
PROTEIN–PROTEIN INTERACTION
MEFV encodes the protein called pyrin (also known as
marenostrin or TRIM20), which is supposed to play a key
role in apoptotic and inflammatory signaling pathways. The
protein belongs to the large family of proteins sharing a
conserved domain structure with the tripartite motif (TRIM)
consisting of an N-terminal RING domain, B-box domain(s)
and a C-terminal coiled-coil domain (Weinert et al., 2015). In
TRIM20 the RING domain with the ubiquitin ligase activity is
replaced by the PYD domain, which belongs to the death domain
superfamily (Martinon et al., 2001; Gumucio et al., 2002; Kohl
and Gruütter, 2004). It also carries an additional ∼200-amino
acid C-terminal B30.2/rfp/PRY/SPRY domain. The majority of
the disease-associated mutations are located in the C-terminal
B30.2 domain.
During the last decade the functions of pyrin have been the
subject of intensive research, and advances in our understanding
of its functionality are the result of identification of its interaction
with different proteins and oligomers. In particular, the PYD
domain, via cognate pyrin domain association, interacts with an
adapter protein denoted apoptosis-associated speck-like protein
with a caspase recruitment domain (ASC; Richards et al.,
2001), and thus participates in the regulation of apoptosis,
inflammation, and IL-1β processing (Gumucio et al., 2002).
The B30.2/rfp/PRY/SPRY domain-mediated protein interactions
indicate the role of this domain as an adaptor module to assemble
macromolecular complexes (Perfetto et al., 2013). As a part of
the pyrin inflammasome, pyrin also acts as a pattern recognition
receptor sensing pathogen modification and inactivation of Rho
GTPases (Xu et al., 2014). Paradoxically, pyrin also acts as a
component directing the inflammasome components, NLRP1,
NLRP3, and pro-caspase 1, to selective autophagic degradation
(Kimura et al., 2015). On its own, the dimerization of B30.2
domains by means of the CHS domain appears to be crucial
for the recognition of higher order oligomers (Weinert et al.,
2015).
REGULATION OF INNATE IMMUNITY BY
PYRIN
Since the positional cloning and characterization of the MEFV
gene in 1997 by two consortia (The French FMF Consortium,
1997; The International FMF Consortium, 1997), numerous
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hypotheses have been proposed explaining the potential role of
the protein encoded in regulation of innate immune responses.
Through N-terminal PYD domain pyrin modulates caspase-
1 and IL-1β activation exerting proinflammatory (Yu et al.,
2006, 2007; Seshadri et al., 2007; Gavrilin et al., 2012) or anti-
inflammatory (Chae et al., 2006; Papin et al., 2007; Hesker et al.,
2012) regulatory effects, depending on the experimental system
employed. In a number of studies the NALP3 inflammasome
complex has been implicated in the pathogenesis of FMF
(Papin et al., 2007; Omenetti et al., 2014). More recently,
homozygous knock-in mice harboring the mouse pyrin protein
fused to the human B30.2 domain containing FMF-associated
mutations has been shown to secrete the large amounts of
IL-1β in a NLRP3-independent manner (Chae et al., 2011)
suggesting the formation of an inflammasome that does not
include NLRP3. The pro-inflammatory feature of the pyrin
function and the formation of the pyrin inflammasome has
been confirmed in several later studies (Gavrilin et al., 2012;
Mankan et al., 2012; Xu et al., 2014), which suggested that
FMF-associated mutations are gain-of-function for pyrin and
pyrin itself promotes ASC oligomerization and forms a caspase-
1-activating complex. To add even more to the complexity of
functions performed by pyrin, a recent study has established
that it is involved in the specific autophagic degradation of
cytoplasmic regulators of innate immunity thus contributing
to the resolution of inflammatory response (Kimura et al.,
2015).
PYRIN AND DANGER SIGNALS
Initially, the similarity of pyrin with other known transcriptional
factors has led to speculations that pyrin may itself be a nuclear
factor (The International FMF Consortium, 1997; Centola
et al., 2000). It has been shown that the protein product of
an alternatively spliced mRNA is able to translocate to the
nucleus (Papin et al., 2000). The subsequent studies, however,
have demonstrated the cytosolic localization of the full-length
pyrin. The first evidence for the interaction of the N-terminal
part of pyrin with microtubules and co-localization of pyrin
with actin has been obtained by Mansfield and co-workers
(Mansfield et al., 2001) suggesting that pyrin is a part of
unique cytoskeleton signaling pathway. Subsequently, Waite
et al. (2009) confirmed this observation by demonstrating the
interaction of pyrin, ASC and actin as well as by identifying new
interactions of pyrin with the adaptor protein PSTPIP1, which
regulates the cytoskeleton and cell migration. Demonstration
of the interaction between the B-box/coiled-coil domains of
pyrin with PSTPIP1, the protein that is mutated in PAPA
syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and
Acne), confirmed the important role played by pyrin in
cytoskeletal signaling pathways (Shoham et al., 2003; Waite et al.,
2009). Mutations in PSTPIP1 increase its affinity to pyrin thus
suggesting a molecular link between FMF and PAPA syndrome
(Shoham et al., 2003).
In a more recent study by Xu et al. (2014) pyrin has
been shown to activate caspase-1 in response to Rho GTPases
modifying toxins from a number of pathogenic bacteria. They
suggested that pyrin recognizes downstream Rho modifications,
most likely involving the actin cytoskeleton modifications (Xu
et al., 2014). Subsequent studies by Kim et al. (2015) confirmed
the link between the aberrant actin depolymerization and
inflammasome formation. Moreover, the authors suggested that
IL-18 but not IL-1β is implicated in the development of
autoinflammatory disease. However, it was shown that pyrin
inflammasome is triggered by the lack of actin polymerization
using inactivation mutation of the actin-depolymerizing cofactor
Wdr1 in mice raised in a gnotobiotic facility (Kim et al.,
2015). Thus, the direct participation of pyrin in bacterial
sensing has been questioned in this study. Moreover, another
interpretation of results by Xu et al. (2014) is that pyrin responds
to the modification and inactivation of the host’s proteins by
bacterial toxins rather than directly detecting a microbial product
(Foley, 2014). In the light of recent findings implicating Rho
GTPase in the direct regulation of the pyrin inflammasome
the role of the host protein modification as a danger signal
is much more prevalent than that of bacterial toxins (Park
et al., 2015). Similarly, pertussis toxin with the abolished ADP-
ribosyltransferase activity is unable to induce pyrin-dependent
inflammasome to cleave pro-IL-1β into the active form (Dumas
et al., 2014). Thus the bacterial toxins or components are not the
primary danger signals for pyrin inflammasome, there must be
modifications of the host proteins in order to be perceived as
danger signals.
The relationship between pyrin and cytoskeleton can be
additionally confirmed by the therapeutic efficiency of colchicine,
an alkaloid with the antimitotic activity, which is recommended
and widely used as the first line therapy for the treatment of FMF
(Zemer et al., 1986). Moreover, responsiveness to colchicine still
has a diagnostic power in FMF. Colchicine exerts various anti-
inflammatory effects mostly related to microtubule disruption
and depolymerization in a dose-dependent manner (Sackett and
Varma, 1993). In a recent study by Taskiran and others the re-
organization of actin cytoskeleton in THP-1 cells by colchicine
has been described (Taskiran et al., 2012). The mechanisms of
its action in FMF have not been completely elucidated and
remain under active investigation. It is generally accepted that
the therapeutic action of colchicine in FMF is mainly due to
the effects on leukocyte migration, signal transduction, and gene
expression (Dinarello et al., 1976; Ben-Chetrit et al., 2006; Chae
et al., 2008).
Pyrin is primarily expressed in cells of myeloid lineage, mainly
polymorphonuclear neutrophils, eosinophils, and monocytes
(Centola et al., 2000). Seemingly unprovoked trafficking of these
cells to the serosal/synovial membranes is a key event in acute
inflammatory attacks of FMF (Ben-Chetrit and Levy, 1998).
The regulatory mechanisms implicated in leukocyte migration
depend on Ca2+ influx and signaling events that result in
changes in cytoskeletal organization, such as assembly and
disassembly of F-actin, which provide forces necessary for cell
migration (Vicente-Manzanares and Sánchez-Madrid, 2004). The
regulation of these activities has recently been shown to involve
the Rho family of small GTPases, including Rho, Rac, and
Cdc42 (Endlich et al., 2001; Provenzano and Keely, 2011). The
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Rho family of GTPases are the key regulators of a variety of
cellular activities including motility, proliferation, apoptosis, and,
particularly, of actin cytoskeleton rearrangements (Spiering and
Hodgson, 2011). It was shown that Rho activation is sufficient
to promote migration of monocytes across endothelial cells
(Honing et al., 2004). In our experiments, we have observed a
phenomenon of heightened sensitivity of neutrophils from FMF
patients toward in vitro conditions in the inductor-free media
(Manukyan et al., 2013a,b). This suggests that the host-derived
stress signals could be responsible for the activation of these cells.
Similar results with the use of monocytes have been obtained later
by another group (Sugiyama et al., 2014). Experiments in vitro
unavoidably impose mechanical forces on cells that may affect
cytoskeletal structure and modulate cellular behavior (Wang
et al., 1993; Matthews et al., 2006). Thus, the routine experimental
procedures involving external mechanical forces applied to cells
may lead to the generation of danger signals that are sensed by
the pyrin inflammasome. Recent investigations showing the pyrin
inflammasome activation in response to actin modifications (Xu
et al., 2014; Kim et al., 2015), together with our results suggesting
the excessive activation of neutrophils from FMF patients in ex
vivo experiments (Manukyan et al., 2013a,b), warrants further
studies of pyrin-cytoskeleton interactions, especially in the case
of FMF.
CLINICAL ASPECTS
Clinically FMF divided into two phenotypes, types 1 and 2
(Shohat and Halpern, 2011). Type 1 is characterized by recurrent
episodes of fever and polyserositis. Fever is the main symptom
of the disease which is present in 95% of acute inflammation
episodes, with the body temperature reaching usually above
38◦C (Sohar et al., 1967). Fever is accompanied by sterile
peritonitis, synovitis, pleuritis, and rarely by pericarditis and
erysipelas-like skin lesions (Shohat and Halpern, 2011). A typical
attack lasts 12 h to 2–3 days and resolves spontaneously. The
frequency, duration, intensity, and symptoms experienced during
attacks are highly variable between patients. During attack-free
period patients are asymptomatic. About 50% of the patients
are reported to have prodromal symptoms (Lidar et al., 2006).
The first clinical presentation of type 2 FMF is amyloidosis, in
the absence of other clinical symptoms (Shohat and Halpern,
2011).
The manifestation of the disease is diverse, ranging from
asymptomatic to the potentially life-threatening states. The main
and potentially lethal complication of the disease is secondary
(AA) amyloidosis, which usually affects the kidneys. Amyloidosis
is the result of tissue deposition of amyloid, which is a proteolytic
cleavage product of the acute phase reactant serum amyloid
A (SAA; Sohar et al., 1967). Overproduction of SAA leads
to the extracellular accumulation of fibrillar protein and the
development of amyloidosis (van der Hilst et al., 2005). Presently
the administration of colchicine (1–3 mg/day) is the preferred
treatment for FMF allowing extended periods of remission as
well as preventing amyloidosis in the majority of FMF patients
(Pras, 1998). Since 5–10% of the patients are colchicine resistant
or intolerant to the drug, the efforts toward developing alternative
treatment were undertaken. As an alternative approach, specific
anti-cytokine therapies, such as IL-1 receptor and tumor necrosis
factor antagonists were tested with a limited number of patients
(Nakamura et al., 2007; Ben-Zvi and Livneh, 2014). Although,
genotyping of the MEFV mutations is the preferred method
in FMF diagnostics, it is confirmatory to the clinical diagnosis.
Presently, there are no definitive biochemical markers that could
serve as diagnostic ones. Usually FMF attacks are accompanied by
a non-specific increase in acute phase reactants such as C-reactive
protein, fibrinogen, and serum amyloid A as well as by the
increased white blood cell count with low-grade neutrophilia.
The diagnosis of FMF remains clinical, since mutations have
reduced penetrance and cannot always be identified on both
alleles (Tunca et al., 2002). Clinical manifestations of FMF
may overlap with the phenotypes of autoinflammatory disorders
and, to a certain degree, with autoimmune diseases, which may
potentially complicate diagnosis of FMF. One distinguishing
feature of autoinflammatory syndroms is responsiveness to IL-
1β blocking therapy, although there are exceptions (Bodar et al.,
2005; Arostegui et al., 2007; Kuijk et al., 2007; Gattorno et al.,
2008).
Several studies have demonstrated association of MEFV
mutations with different inflammatory pathologies, such as
systemic onset juvenile idiopathic arthritis (Uslu et al., 2010),
inflammatory bowel disease (Akyuz et al., 2013), Behçet’s disease
(Atagunduz et al., 2003), ulcerative colitis (Giaglis et al., 2006),
Fibromyalgia syndrome (Feng et al., 2009), rheumatoid arthritis
(Rabinovich et al., 2005), ankylosing spondylitis (Akkoc et al.,
2010), and others. Other pathologies, which are associated with
mutations in the MEFV gene, are two vasculitis types, Henoch-
Schonlein Purpura (Gershoni-Baruch et al., 2003; Tunca et al.,
2005) and polyarteritis nodosa (Tunca et al., 2005; Aksu and
Keser, 2011). Clinical manifestations of these vasculitis types,
which accompany FMF, might be considered as a clinical
manifestation of the latter. The diseases listed represent multi-
factorial immunological disorders with a marked involvement
of the inflammatory component. A growing number of similar
cases, which are reported to be associated with the MEFV gene,
TABLE 1 | Structural and functional roles of pyrin in cellular processes.
Role Reference
Inflammasome assembly Chae et al., 2011; Perfetto et al., 2013;
Vajjhala et al., 2014
Sensing intracellular danger signals by
the inflammasome (aberrant actin
depolymerisation, protein modification
by bacterial toxins)
Dumas et al., 2014; Xu et al., 2014;
Kim et al., 2015
Activation of mediators of inflammation
by the inflammasome (IL-1β, IL-18)
Chae et al., 2011; Kim et al., 2015
Pyrin-cytoskeloton interactions Mansfield et al., 2001; Shoham et al.,
2003; Waite et al., 2009
Apoptosis Martinon et al., 2001; Richards et al.,
2001; Gumucio et al., 2002
Autophagy of innate immunity
regulators
Mandell et al., 2014; Kimura et al., 2015
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suggest that pyrin is a key regulatory element of the innate
immune responses and can affect inflammatory processes during
these disorders.
CONCLUDING REMARKS
Understanding the role of pyrin in innate immunity has
progressed rapidly in recent years, uncovering its numerous
functions in the cell from the formation of several supramolecular
structures and inflammasome assembly, to sensing various
intracellular danger signals, to mounting the innate immune
responses, and to the resolution of inflammation (Table 1).
The evidences for positive selection of mutations in the
MEFV gene are given in several works cited in this review,
and they have a strong support from the formal analytical
approaches of population genetics. What remains unclear,
however, why the mutations have been selected and maintained
in the Mediterranean populations and what are the mechanistic
explanations for the advantage at the biochemical level?
In particular, we know well about the negative effects of
the homozygous or compounded heterozygous mutant allele
combination, which result in a higher morbidity/mortality rate.
At the cellular level this genetics presumably results in the
impaired assembly of pyrin inflammasomes, in the launch of
excessive and extended inflammatory responses, and in a less
efficient resolution of inflammation. Given the multiple functions
of pyrin and the expected pleiotropic effects of mutations in
the MEFV gene, the significance and contribution of each of
these functions are difficult to ascertain in terms of clinical
presentation in pathology or the heterozygote advantage at the
phenotypic level. All we know at the clinical level is that the
homozygous or compounded heterozygous state results in the
enhanced and extended inflammatory response to some of the
innocuous factors that are tolerated well and handled efficiently
by the normal immune system. The diseased state is certainly
disadvantageous (although it cannot be excluded that certain
conditions in the past have been conducive to select such traits)
but we don’t know about the possible advantages conferred by
the heterozygote state. Investigation of this previously ignored
group could potentially reveal the characteristics and traits that
were responsible for the selective advantage and maintenance of
these mutations in the Mediterranean populations.
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